Selank

What is Selank?

Selank is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is an analog of the naturally occurring immunopeptide tuftsin (Thr-Lys-Pro-Arg), a tetrapeptide derived from the enzymatic cleavage of immunoglobulin G (IgG) in the spleen. Selank extends the tuftsin sequence with a C-terminal Pro-Gly-Pro tripeptide that enhances metabolic stability and prolongs biological activity.[11]

Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank has been the subject of extensive research since the 1990s. Unlike classical benzodiazepine compounds, Selank produces anxiety-modulating effects through a distinct mechanism — acting as a positive allosteric modulator of GABA receptors in a concentration-dependent manner without the sedation, memory impairment, or dependence risk associated with benzodiazepines.[5][11]

Research interest in Selank spans anxiety and stress modulation, immunomodulation and inflammation, cognitive research applications, enkephalin metabolism, and antiviral activity. The peptide retains the immunomodulatory properties of its parent molecule tuftsin while demonstrating additional CNS effects not observed with the native tetrapeptide.[14]

Selank is classified as a research compound. It has not been approved by the FDA for any therapeutic indication. All information presented here reflects findings from published preclinical and clinical studies.

Mechanism of Action

Selank’s biological effects are mediated through several interrelated molecular pathways spanning both the nervous and immune systems:[11][2]

• GABAergic Allosteric Modulation: Selank acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission without binding to the classical benzodiazepine site. Transcriptomic analysis revealed 45 genes with altered expression following Selank administration, predominantly in GABAergic signaling pathways.[2][4]
• Enkephalin-Degrading Enzyme Inhibition: Selank inhibits enkephalin-degrading enzymes (aminopeptidase N and carboxypeptidase) with an IC50 of 20 µM — stronger than established inhibitors puromycin and bacitracin. This elevates endogenous enkephalin levels, contributing to anxiety-modulating and analgesic activity through the opioid system.[19]
• Cytokine and Chemokine Regulation: Selank decreases pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) while modulating inflammation-resolving mediators (IL-4). Transcriptomic studies show rapid time-dependent alterations in inflammation-related gene expression within 30-90 minutes of administration.[6][14]
• BDNF Modulation: In ethanol-exposed aging models, Selank regulated BDNF content in hippocampus and prefrontal cortex, preventing cognitive impairment — linking its cognitive research effects to neurotrophin signaling.[3]
• Opioid System Interaction: Naloxone blockade studies revealed strain-dependent opioid system involvement in Selank’s anxiety-modulating mechanism, with the opioid contribution varying by baseline anxiety phenotype.[15]

Key Research Findings

Anxiety-modulating Research

Anxiety modulation represents the most extensively studied application of Selank. Medvedev et al. (2014) published clinical data from a comparative study of 60 patients with phobic-anxiety and somatoform disorders, demonstrating that Selank produced pronounced anxiety-modulating effects with mild cognitive research benefits. Critically, effects persisted one week after treatment cessation, and the peptide showed favorable tolerability compared to the benzodiazepine phenazepam.[5]

Medvedev et al. (2015) followed with optimization data showing that combined Selank-phenazepam treatment accelerated therapeutic benefits while reducing benzodiazepine adverse effects including sedation, memory impairment, and sexual dysfunction — suggesting Selank may enable benzodiazepine dose reduction strategies.[12]

The GABAergic molecular basis for Selank’s anxiety-modulating effects was characterized by Volkova et al. (2016), who demonstrated that Selank altered expression of 45 genes involved in GABAergic neurotransmission within one hour of administration. The effects included modulation of GABA receptor subunit expression and related signaling genes.[2]

Vyunova et al. (2018) published a mechanistic review establishing that Selank acts as a positive allosteric modulator of GABA receptors in a concentration-dependent manner — a mechanism distinct from classical benzodiazepine binding, which may explain the absence of sedation and dependence.[11]

Kasian et al. (2017) demonstrated that Selank enhanced diazepam’s anxiety-modulating effects under chronic unpredictable mild stress conditions, with the combination producing superior anxiety reduction through synergistic GABAergic mechanisms.[10]

Povarov et al. (2017) provided electrophysiological evidence that Selank increased amplitude and discharge rate of spontaneous inhibitory postsynaptic currents in hippocampal CA1 pyramidal neurons, directly confirming enhancement of GABAergic transmission at the synaptic level.[8]

The opioid system’s contribution to Selank’s anxiety-modulating mechanism was dissected by Kozlovskii et al. (2012), who showed that naloxone blocked Selank’s anxiety-modulating effects in high-anxiety mice but enhanced them in low-anxiety mice — revealing a strain-dependent opioid component that may explain individual response variation.[15]

Immunomodulation & Antiviral Research

As a derivative of the immunopeptide tuftsin, Selank retains significant immunomodulatory activity. Yasenyavskaya et al. (2021) demonstrated that under social stress conditions, Selank decreased pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, and TGF-β1 while restoring inflammation-resolving IL-4 levels — providing a direct immunological basis for its stress-protective effects.[6]

Kolomin et al. (2014) characterized the temporal dynamics of Selank’s immunomodulatory action, showing rapid time-dependent alterations in inflammation-related genes (C3, Casp1, Il2rg, Xcr1) in mouse spleen within 30-90 minutes of injection — indicating the peptide engages immune pathways with notable speed.[14]

Earlier work by Kolomin et al. (2011) identified approximately 34 inflammation-related genes altered by Selank in mouse spleen, with particularly significant changes in Bcl6 — a transcription factor governing immune system development and germinal center formation.[17]

Kolomin et al. (2011) also demonstrated that Selank and its Gly-Pro fragment significantly altered chemokine, cytokine, and receptor gene expression 6-24 hours after administration, establishing a comprehensive profile of immunogenomic modulation.[18]

Antiviral properties have been documented by Ershov et al. (2009), who showed Selank completely suppressed influenza A virus (H3N2) reproduction in vitro and promoted survival in animal models by inducing interferon-alpha production without affecting IL-4, IL-10, or TNF-alpha levels.[16]

Cognitive & Behavioral Research

Selank’s cognitive research properties have been investigated across several cognitive domains. Kolik et al. (2019) demonstrated that Selank prevented ethanol-induced memory and attention disturbances in aging animals by regulating BDNF levels in hippocampus and prefrontal cortex — establishing a neurotrophin-mediated mechanism for cognitive protection.[3]

Semenova et al. (2007) showed that Selank at 300 µg/kg restored cognitive processes disrupted by developmental catecholaminergic damage, improving learning, memory, and sensory attention — suggesting the peptide can compensate for neurodevelopmental deficits in catecholamine systems.[13]

Sarkisova et al. (2008) examined Selank’s antidepressant-like effects in genetically predisposed WAG/Rij rats and BALB/c mice, reporting that high-dose Selank (1000-2000 µg/kg) counteracted depression-like symptoms including reducing forced swimming immobility and anhedonia in genetically susceptible strains.[9]

Kolik et al. (2016) demonstrated that Selank inhibited ethanol-induced hyperlocomotion and motor sensitization in DBA/2 mice at 0.3 mg/kg, with effects attributed to opioid system modulation — suggesting relevance to alcohol-related behavioral research.[7]

Konstantinopolsky et al. (2022) extended the behavioral research by showing Selank reduced morphine withdrawal syndrome by 39.6% and significantly attenuated convulsive reactions, ptosis, and posture disorders in rats — indicating potential relevance to opioid dependence research.[1]

Meshavkin et al. (2006) provided mechanistic evidence that Selank’s effects on dopamine system hyperfunction are mediated through enkephalin-degrading enzyme inhibition rather than direct dopamine receptor binding, clarifying the neuromodulatory pathway.[19]

Summary of Research

Selank occupies a unique position in peptide research as a dual anxiety-modulating and immunomodulatory compound derived from the naturally occurring immunopeptide tuftsin. Published literature spanning over two decades documents activity across multiple systems:

• Anxiety-modulating: GABAergic allosteric modulation with clinical evidence of anxiety-modulating effects comparable to benzodiazepines, without sedation, memory impairment, or dependence risk.[5][11]
• Immunomodulation: Rapid cytokine regulation, inflammation-related gene modulation, and antiviral activity via interferon-alpha induction — retaining tuftsin’s immune properties.[6][14]
• Cognitive: BDNF-mediated neuroprotection, restoration of catecholamine-disrupted learning, and protection against ethanol-induced cognitive impairment.[3][13]
• Enkephalin System: Potent inhibition of enkephalin-degrading enzymes (IC50: 20 µM), contributing to opioid-mediated anxiety-modulating and behavioral effects.[19]
• Behavioral: Antidepressant-like effects in genetically susceptible models and attenuation of substance-related behavioral disturbances.[1][9]

While preclinical evidence is substantial and limited clinical data exists from Russian anxiety disorder studies, controlled human clinical trials in Western regulatory frameworks remain absent. Selank has not been approved for therapeutic use by the FDA or EMA. Ongoing research continues to explore the peptide’s unique dual anxiety-modulating and immunomodulatory profile.

Frequently Asked Questions

Citations